.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,877,245

« Back to Dashboard

Details for Patent: 8,877,245

Title:Modified release dosage forms of skeletal muscle relaxants
Abstract: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once--daily oral administration to maintain an adequate plasma concentration--time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
Inventor(s): Venkatesh; Gopi (Vandalia, OH), Clevenger; James M. (Vandalia, OH)
Assignee: Aptalis Pharmatech, Inc. (Vandalia, OH)
Filing Date:Aug 09, 2012
Application Number:13/570,670
Claims:1. A method of relieving muscle spasms in a patient in need thereof comprising administering a pharmaceutical dosage form comprising a population of extended release beads, wherein said extended release beads comprise: an active-containing core particle comprising cyclobenzaprine hydrochloride as the active; and an extended release coating comprising a water insoluble polymer membrane surrounding said core, wherein said water insoluble polymer membrane comprises a polymer selected from the group consisting of ethers of cellulose, esters of cellulose, cellulose acetate, ethyl cellulose, polyvinyl acetate, neutral copolymers based on ethyl acrylate and methyl methacrylate, copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups, pH-insensitive ammonio methacrylic acid copolymers, and mixtures thereof; wherein the total amount of cyclobenzaprine hydrochloride in the pharmaceutical dosage form is 30 mg; wherein following a single oral administration of the pharmaceutical dosage form, the pharmaceutical dosage form provides a maximum blood plasma concentration (Cmax) of 19.851.+-.5.8765 ng/mL of cyclobenzaprine HCl and an AUC.sub.0-168 of 736.60.+-.259.414 nghr/mL.

2. A method of relieving muscle spasms in a patient in need thereof comprising administering a pharmaceutical dosage form comprising a population of extended release beads, wherein said extended release beads comprise: an active-containing core particle comprising cyclobenzaprine hydrochloride as the active; and an extended release coating comprising a water insoluble polymer membrane surrounding said core, wherein said water insoluble polymer membrane comprises a polymer selected from the group consisting of ethers of cellulose, esters of cellulose, cellulose acetate, ethyl cellulose, polyvinyl acetate, neutral copolymers based on ethyl acrylate and methyl methacrylate, copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups, pH-insensitive ammonio methacrylic acid copolymers, and mixtures thereof; wherein the total amount of cyclobenzaprine hydrochloride in the pharmaceutical dosage form is 30 mg; wherein following a single oral administration of the pharmaceutical dosage form, the pharmaceutical dosage form provides a maximum blood plasma concentration (Cmax) of 19.851.+-.5.8765 ng/mL of cyclobenzaprine HCl and an AUC.sub.0-.infin. of 779.889.+-.277.6349 nghr/mL.

3. A method of relieving muscle spasms in a patient in need thereof comprising administering a pharmaceutical dosage form comprising a population of extended release beads, wherein said extended release beads comprise: an active-containing core particle comprising cyclobenzaprine hydrochloride as the active; and an extended release coating comprising a water insoluble polymer membrane surrounding said core, wherein said water insoluble polymer membrane comprises a polymer selected from the group consisting of ethers of cellulose, esters of cellulose, cellulose acetate, ethyl cellulose, polyvinyl acetate, neutral copolymers based on ethyl acrylate and methyl methacrylate, Copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups, pH-insensitive ammonio methacrylic acid copolymers, and mixtures thereof; wherein the total amount of cyclobenzaprine hydrochloride in the pharmaceutical dosage form is 15 mg; wherein following a single oral administration of the pharmaceutical dosage form, the pharmaceutical dosage form provides a maximum blood plasma concentration (Cmax) of 8.315.+-.2.1635 ng/mL of cyclobenzaprine HCl and an AUC.sub.0-168 of 318.30.+-.114.657 nghr/mL.

4. A method of relieving muscle spasms in a patient in need thereof comprising administering a pharmaceutical dosage form comprising a population of extended release beads, wherein said extended release beads comprise: an active-containing core particle comprising cyclobenzaprine hydrochloride as the active; and an extended release coating comprising a water insoluble polymer membrane surrounding said core, wherein said water insoluble polymer membrane comprises a polymer selected from the group consisting of ethers of cellulose, esters of cellulose, cellulose acetate, ethyl cellulose, polyvinyl acetate, neutral copolymers based on ethyl acrylate and methyl methacrylate, copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups, pH-insensitive ammonio methacrylic acid copolymers, and mixtures thereof; wherein the total amount of cyclobenzaprine hydrochloride in the pharmaceutical dosage form is 15 mg; wherein following a single oral administration of the pharmaceutical dosage form, the pharmaceutical dosage form provides a maximum blood, plasma concentration (Cmax) of 8.315.+-.2.1635 ng/mL of cyclobenzaprine HCl and an AUC.sub.0-.infin. of 354.075.+-.119.8037 nghr/mL.

5. A method of relieving muscle spasms in a patient in need thereof comprising administering a pharmaceutical dosage form comprising a population of extended release beads, Wherein said extended release beads comprise: an active-containing core particle comprising cyclobenzaprine hydrochloride as the active; and an extended release coating comprising a water insoluble polymer membrane surrounding said core, wherein said water insoluble polymer membrane comprises a polymer selected from the group consisting of ethers of cellulose, esters of cellulose, cellulose acetate, ethyl cellulose, polyvinyl acetate, neutral copolymers based on ethyl acrylate and methyl methacrylate, copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups, pH-insensitive ammonio methacrylic acid copolymers, and mixtures thereof; wherein the total amount of cyclobenzaprine hydrochloride in the pharmaceutical dosage form is 30 mg; wherein following a single oral administration, said pharmaceutical dosage form provides a maximum blood plasma concentration (Cmax) within the range of about 80% to 125% of about 20 ng/mL of cyclobenzaprine and an AUC.sub.0-168 within the range of about 80% to 125% of about 740 nghr/mL.

6. The method of any one of claims 1-4, wherein said pharmaceutical dosage form when dissolution tested using United States Pharmacopoeia Apparatus 2 (paddled @ 50 rpm) in 900 mL of 0.1N HCl at 37.degree. C., exhibits a release profile substantially corresponding to the following pattern: after 2 hours, no more than 40% of the total amount of the cyclobenzaprine hydrochloride is released; after 4 hours, from about 40-65% of the total amount of the cyclobenzaprine hydrochloride is released; and after 8 hours, from about 60-85% of the total amount of the cyclobenzaprine hydrochloride is released.

7. The method of any one of claims 1-5, wherein said pharmaceutical dosage form when dissolution tested using United States Pharmacopoeia Apparatus 2 (paddled @ 50 rpm) in 900 mL of 0.1N HCl at 37.degree. C. exhibits a release profile substantially corresponding to the following pattern; after 2 hours, no more than 40% of the total amount of the cyclobenzaprine hydrochloride is released; after 4 hours, from about 40-65% of the total amount of the cyclobenzaprine hydrochloride is released; after 8 hours, from about 60-85% of the total amount of the cyclobenzaprine hydrochloride is released; and after 12 hours, from about 75-85% of the total amount of the cyclobenzaprine hydrochloride is released.

8. The method of any one of claims 1-5, wherein said extended release coating comprises from about 7% to 12% by weight of the extended release beads.

9. The method of any one of claims 1-5, wherein said extended release coating further comprises a water soluble polymer selected from the group consisting of methylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, polyethylene polyvinylpyrrolidone and mixtures thereof.

10. The method of any one of claims 1-5, wherein said extended release coating further comprises a plasticizer selected from the group consisting of triacetin, tributyl citrate, triethyl citrate, acetyl tri-n-butyl citrate, diethyl phthalate, dibutyl sebacate, polyethylene glycol, polypropylene glycol, castor oil, acetylated mono- and di-glycerides, and mixtures thereof.

11. The method of claim 10, wherein said extended release coating comprises about 10% to 25% by weight of said plasticizer.

12. The method of any one of claims 1-5, wherein said pharmaceutical dosage form in the form of a capsule.

13. The method of any one of claims 1-5, wherein said extended release coating comprises about 1% to about 15% by weight of the extended release heads.

14. The method of any one of claims 1-5, wherein said pharmaceutical dosage form further comprises a seal coating layer comprising hydroxypropyl methylcellulose or hydroxypropylcellulose.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc